Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameInt Medical
Stock Code01501
Company Full NameTo be extracted
Industry医疗器械
Principal Activities我們是中國領先的心內介入器械製造商。主要產品包括球囊擴張壓力泵、導管鞘套裝、造影導絲、動脈壓迫止血帶、Y型連接器套裝、壓力延長管、三通旋塞及造影導管,主要用於心血管介入手術(特別是PCI手術)。
Listing Date2019-11-08
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市嘉定區金園一路925號2幢
Business Address (Hong Kong)香港銅鑼灣勿地臣街1號時代廣場二座31樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitekdl-int.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 20.80 / shares
Offer Price RangeTo be extracted
Lot Size200 shares
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2019-10-28 to 2019-10-31
Global Offering Shares40,000,000 shares
HK Public Offer Shares (Initial)4,000,000 shares (10.0%)
Public Offer Lots (Initial)20,000lots (Pool A10,000lots,Pool B10,000lots)
International Placing Shares (Initial)36,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO160,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share28.3%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 832,000,000

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 4,160
2 lots 400 HK$ 8,320
3 lots 600 HK$ 12,480
4 lots 800 HK$ 16,640
5 lots 1,000 HK$ 20,800
6 lots 1,200 HK$ 24,960
7 lots 1,400 HK$ 29,120
8 lots 1,600 HK$ 33,280
9 lots 1,800 HK$ 37,440
10 lots 2,000 HK$ 41,600
15 lots 3,000 HK$ 62,400
20 lots 4,000 HK$ 83,200
25 lots 5,000 HK$ 104,000
30 lots 6,000 HK$ 124,800
35 lots 7,000 HK$ 145,600
40 lots 8,000 HK$ 166,400
45 lots 9,000 HK$ 187,200
50 lots 10,000 HK$ 208,000
100 lots 20,000 HK$ 416,000
150 lots 30,000 HK$ 624,000
200 lots 40,000 HK$ 832,000
250 lots 50,000 HK$ 1,040,000
300 lots 60,000 HK$ 1,248,000
350 lots 70,000 HK$ 1,456,000
400 lots 80,000 HK$ 1,664,000
450 lots 90,000 HK$ 1,872,000
500 lots 100,000 HK$ 2,080,000
750 lots 150,000 HK$ 3,120,000
1,000 lots 200,000 HK$ 4,160,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,250 lots 250,000 HK$ 5,200,000
1,500 lots 300,000 HK$ 6,240,000
1,750 lots 350,000 HK$ 7,280,000
2,000 lots 400,000 HK$ 8,320,000
2,250 lots 450,000 HK$ 9,360,000
2,500 lots 500,000 HK$ 10,400,000
3,000 lots 600,000 HK$ 12,480,000
3,500 lots 700,000 HK$ 14,560,000
4,000 lots 800,000 HK$ 16,640,000
4,500 lots 900,000 HK$ 18,720,000
5,000 lots 1,000,000 HK$ 20,800,000
7,500 lots 1,500,000 HK$ 31,200,000
10,000 lots 2,000,000 HK$ 41,600,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 6.81B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +42%

Valuation & Financials

Market Cap (at Offer Price)HK$ 3,272,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币58.2百万元
Period-End Cash Balance人民币298.2百万元
Listing Expenses~HK$ 73,500,000
Listing Expenses / Funds Raised~8.83%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018
Profit for the year 34,00140,77058,236
Balance Sheet
Item 201620172018
Cash and cash equivalents 64,445146,702298,164
Trade and bills receivables 66,29511,3757,085
Inventories 16,14629,46839,015
Total current assets 148,610189,683347,630
Total assets 186,092232,456482,040
Total current liabilities 20,21427,23442,734
Total liabilities 26,64832,242100,730
Total equity 159,444200,214381,310
Equity attributable to owners 159,444200,214372,025
Cash Flow Statement
Item 2016201720182019-04
Net cash from operating activities 38,91039,32466,492
Net cash from investing activities -12,88345,675-39,584
Net cash from financing activities -12,8000121,896
Net increase in cash 13,22784,999148,804
Purchase of PP&E -12,333-12,180-34,554-10,877
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 27.0
First Day OpenHK$ 27.0
First Day Change29.81%
First Day Volume32637500.0
First Day Turnover899357000.0
Use of Proceeds
1、凈所得款項中的約34.1%或258.5百萬港元,擬用于建設位于上海市嘉定區的研發中心及其他設施; 2、凈所得款項中的約14.4%或109.2百萬港元,將用于開發現有管線產品并將其商業化,以及進一步拓展其產品供應; 3、凈所得款項中的約13.8%或104.6百萬港元,將用于購買額外生產設備并替換現有生產設備及將生產線自動化; 4、凈所得款項中的約8.7%或65.9百萬港元,將用于擴大其分銷網絡及覆蓋范圍、與當地分銷商的合作及加大營銷力度; 5、凈所得款項中的約19.6%或148.6百萬港元,將用于為潛在戰略投資(包括收購、合伙及外部授權)提供資金; 6、凈所得款項中的約9.4%或71.2百萬港元,將用于一般企業用途和為其營運資金提供資金。

Underwriting Syndicate

Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Overall Coordinators (2)
交银国际证券有限公司 CE APJ121 招银国际融资有限公司 CE AVM940
Joint Bookrunners (2)
交银国际证券有限公司 CE APJ121 招银国际融资有限公司 CE AVM940
Joint Lead Managers (2)
交银国际证券有限公司 CE APJ121 招银国际融资有限公司 CE AVM940

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Worldwide Healthcare Trust PLC 235,306,240 HKD — 28.28% — 6 months 2020-05-08

Directors & Management

PositionChinese nameEnglish Name
Chairman梁棟科—
Company Secretary宋媛、梁瑞冰—
No director data available.

Major Shareholders

Major Shareholders & Holdings康德萊及其控股方合共持股26.79%;寧波懷格泰益持股15.75%;梁棟科持股5.96%;OrbiMed Capital LLC持股7.07%(H股基石投资)
About this page

This page shows Int Medical (01501) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect